Nature Biotechnology, Published online: 07 July 2026; doi:10.1038/s41587-026-03214-0
A new class of biotech buyer is emerging, as frontier AI and big tech companies acquire early-stage biology foundational platforms. How do big tech acquisitions differ from traditional pharma exits, and what are the potential implications for founders, investors and the pharmaceutical industry?